UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
| Date of report (Date of earliest event reported) | March 3, 2011 |
| HI-TECH PHARMACAL CO., INC. |
| (Exact Name of Registrant as Specified in Its Charter) |
| |
| Delaware |
| (State or Other Jurisdiction of Incorporation) |
| No. 0-20424 | 11-2638720 |
| (Commission File Number) | (IRS Employer Identification No.) |
| | |
| 369 Bayview Avenue, Amityville, New York | 11701 |
| (Address of Principal Executive Offices) | (Zip Code) |
| (631) 789-8228 |
| (Registrant’s Telephone Number, Including Area Code) |
| |
| |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On March 3, 2011, Hi-Tech Pharmacal Co., Inc. (the “Company”) issued a press release announcing that as a result of the U.S. Food and Drug Administration’s press release, ECR Pharmaceuticals Co., Inc. (“ECR”), a wholly owned subsidiary of the Company, must stop shipment of three cough/cold and allergy related products currently marketed by ECR within 180 days after March 3, 2011. A copy of the press release is attached hereto as Exhibit 99.1 to this current report and is incorporated herein by reference.
Exhibit 9.01. Financial Statements and Exhibits
| Exhibit Number | Description |
Exhibit 99.1 | Press Release dated March 3, 2011 of Hi-Tech Pharmacal Co., Inc. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 3, 2011 | HI-TECH PHARMACAL CO., INC. | |
| | | | |
| | /s/ David S. Seltzer | |
| | Name: David S. Seltzer | |
| | Title: President and Chief Executive Officer | |
| | | | |
INDEX TO EXHIBITS
| Exhibit Number | Description |
Exhibit 99.1 | Press Release dated March 3, 2011 of Hi-Tech Pharmacal Co., Inc. |
